Analyst Price Target is $2.50
▲ +47.06% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Assembly Biosciences in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 47.06% upside from the last price of $1.70.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Assembly Biosciences. This rating has held steady since August 2022, when it changed from a Hold consensus rating.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.